S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

TEVA Teva Pharmaceutical Industries Ltd

22.0201

0.7101 (3.33%)

Dec 20 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Teva Pharmaceutical Indu... Charts.

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Teva Pharmaceutical Indu... Charts.

Teva Pharmaceutical Industries Ltd News

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
Friday 20 December 2024 (2 days ago) • GlobeNewswire Inc.

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Tuesday 17 December 2024 (6 days ago) • GlobeNewswire Inc.

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Wednesday 11 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Thursday 5 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
Wednesday 4 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
Monday 25 November 2024 (4 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 21 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 20 November 2024 (1 month ago) • Edgar (US Regulatory)

Teva to Present at the Jefferies London Healthcare Conference
Friday 8 November 2024 (1 month ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 6 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 6 November 2024 (2 months ago) • Edgar (US Regulatory)

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
Wednesday 6 November 2024 (2 months ago) • GlobeNewswire Inc.

More Teva Pharmaceutical Industries Ltd News Articles

Asia Broadband (PK)

Anavex Life Sciences

Lightwave Logic

Digital Brand Media and ... (PK)

Elite Pharmaceuticals (QB)

Good Vibrations Shoes (PK)

Kraig Biocraft Laborator... (QB)

Northwest Biotherapeutics (QB)

Fannie Mae (QB)

Code Green Apparel (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions